These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 38042600)

  • 21. TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy.
    Li P; Liu R; Lin J; Ji Y
    J Biopharm Stat; 2020 Nov; 30(6):979-992. PubMed ID: 32951518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CUSUMIN: A cumulative sum interval design for cancer phase I dose finding studies.
    Hatayama T; Yasui S
    Pharm Stat; 2022 Nov; 21(6):1324-1341. PubMed ID: 35833753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Perils of Misspecified Priors and Optional Stopping in Multi-Armed Bandits.
    Loecher M
    Front Artif Intell; 2021; 4():715690. PubMed ID: 34308342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Small-sample behavior of novel phase I cancer trial designs.
    Oron AP; Hoff PD
    Clin Trials; 2013 Feb; 10(1):63-80. PubMed ID: 23345304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
    Guo B; Li Y
    Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An empirical evaluation of active inference in multi-armed bandits.
    Marković D; Stojić H; Schwöbel S; Kiebel SJ
    Neural Netw; 2021 Dec; 144():229-246. PubMed ID: 34507043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Performance of phase-I dose finding designs with and without a run-in intra-patient dose escalation stage.
    Labrenz J; Edelmann D; Heitmann JS; Salih HR; Kopp-Schneider A; Schlenk RF
    Pharm Stat; 2023 Mar; 22(2):236-247. PubMed ID: 36285348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generalized phase I-II designs to increase long term therapeutic success rate.
    Thall PF; Zang Y; Yuan Y
    Pharm Stat; 2023; 22(4):692-706. PubMed ID: 37038957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
    Lin R; Yin G
    Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A dose-finding design for phase I clinical trials based on Bayesian stochastic approximation.
    Xu J; Zhang D; Mu R
    BMC Med Res Methodol; 2022 Oct; 22(1):258. PubMed ID: 36183071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship.
    Guo B; Li Y
    BMC Med Res Methodol; 2014 Jul; 14():95. PubMed ID: 25074481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An optimization algorithm for designing phase I cancer clinical trials.
    Jiang H; Liu Y; Su Z
    Contemp Clin Trials; 2008 Mar; 29(2):102-8. PubMed ID: 17681867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Bayesian dose finding design for dual endpoint phase I trials.
    Loke YC; Tan SB; Cai Y; Machin D
    Stat Med; 2006 Jan; 25(1):3-22. PubMed ID: 16013039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bayesian interval-based oncology dose-finding design with repeated quasi-continuous toxicity model.
    Zhao D; Zhu J; Wang L
    Contemp Clin Trials; 2021 Mar; 102():106265. PubMed ID: 33418097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bayesian optimal interval design for dose finding in drug-combination trials.
    Lin R; Yin G
    Stat Methods Med Res; 2017 Oct; 26(5):2155-2167. PubMed ID: 26178591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bayesian adaptive model selection design for optimal biological dose finding in phase I/II clinical trials.
    Lin R; Yin G; Shi H
    Biostatistics; 2023 Apr; 24(2):277-294. PubMed ID: 34296266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of Deviation From Planned Cohort Size and Operating Characteristics of Phase 1 Trials.
    Park M; Liu S; Yap TA; Yuan Y
    JAMA Netw Open; 2021 Feb; 4(2):e2037563. PubMed ID: 33595664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes.
    Koopmeiners JS; Modiano J
    Clin Trials; 2014 Feb; 11(1):38-48. PubMed ID: 24082004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early completion of phase I cancer clinical trials with Bayesian optimal interval design.
    Kojima M
    Stat Med; 2021 Jun; 40(14):3215-3226. PubMed ID: 33844323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2.
    Guo W; Wang SJ; Yang S; Lynn H; Ji Y
    Contemp Clin Trials; 2017 Jul; 58():23-33. PubMed ID: 28458054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.